The PneumEx Study

  • Research type

    Research Study

  • Full title

    The PneumEx Study: Experimental Human Pneumococcal Carriage and Exhaled Pneumococcal Biomarkers

  • IRAS ID

    269714

  • Contact name

    Andrea Collins

  • Contact email

    Andrea.Collins@lstmed.ac.uk

  • Sponsor organisation

    Liverpool School of Tropical Medicine

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    The aim of this study is to assess if ‘BreathSpec’ and the ‘Exhaled Detection Facemask’ (EDF) are able to identify and quantify Streptococcus pneumoniae (pneumococcus) in exhaled breathe from participants who have had pneumococcus experimentally introduced into their nose.

    Antimicrobial resistance is a growing problem all over the world. In order to address this, better diagnostic tests are urgently needed to improve our antibiotic use. Currently only 50-73% of patients with pneumonia have an underlying cause identified - this leads to poor antibiotic prescribing. This study uses two new diagnostic devices that we hope could identify the presence of the leading cause of pneumonia, Streptococcus pneumoniae. The first device, BreathSpec, analyses chemicals that are present in exhaled breath. We are looking for a specific ‘signature’ that indicates the presence of pneumococcus. The second, EDF, is a facemask that collects microbiology samples from exhaled breath, in order to advance our knowledge of how pneumonia is spread.

    The ‘Experimental Human Pneumococcal challenge’ (EHPC) model allows us to perform both BreathSpec and EDF before and after the bacteria is experimentally introduced into a participant’s nose. As a result, we can use the two devices to assess the changes occurring when the bacteria is present.

    Clinical trial plan is to perform BreathSpec (breathing into a machine) and EDF (wearing a facemask for half an hour) in 50 participants who have had pneumococcus put up their nose. Samples will then be collected intermittently for the following month.

    The EHPC model has been used in over 1000 adults in Liverpool for the past nine years safely with no serious side effects (participants were required to report any symptoms to the clinical team). Both devices involved in the study collect samples from exhaled breath only.

    In future these data may contribute to the development of devices that better identify the cause of pneumonia and guide targeted antibiotic treatment.

  • REC name

    North West - Liverpool Central Research Ethics Committee

  • REC reference

    19/NW/0586

  • Date of REC Opinion

    16 Oct 2019

  • REC opinion

    Favourable Opinion